This trial is !
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Renal Cell Carcinoma
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma

Provided treatments

  • Biological: Nivolumab
  • Drug: Cabozantinib
  • Drug: Sunitinib
  • Biological: Ipilimumab
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03141177. The sponsor of the trial is Bristol-Myers Squibb and it is looking for 630 volunteers for the current phase.
Official trial title:
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma